Ariën Schiepers

May 22, 2024 | biorxiv.org | Alexander Cohen |Jennifer R. Keeffe |Ariën Schiepers |Sandra E. Dross

AbstractImmunization with mosaic-8b [60-mer nanoparticles presenting 8 SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs)] elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses.

Feb 9, 2024 | biorxiv.org | Alexander Cohen |Jennifer R. Keeffe |Ariën Schiepers |Sandra E. Dross

AbstractImmunization with mosaic-8b [60-mer nanoparticles presenting 8 SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs)] elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses.